GlassScriptPhysician profile
Beata Destan
NPI 1154096691
$401.23
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $401.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.59 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.92 | 2022 | |
| Glaxosmithkline, LLC. | $46.01 | 2022 | |
| Amgen INC. | $34.83 | 2022 | |
| Bausch Health US, LLC | $24.09 | 2022 | |
| Abbvie INC. | $21.08 | 2022 | |
| Genentech USA, INC. | $19.28 | 2022 | |
| Merck Sharp & Dohme LLC | $18.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.99 | 2022 | |
| Novo Nordisk INC | $14.96 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.93 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beata Destan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.